Input Parameters and their levels. حسب Charles Sarala Rubi (21608723)

الموضوعات:

Impact of B₄C & Fly ash on the Density of AMCs. حسب Charles Sarala Rubi (21608723)

الموضوعات:

Effect of Load on GRG. حسب Charles Sarala Rubi (21608723)

الموضوعات:

Surface structure of B₄C. حسب Charles Sarala Rubi (21608723)

الموضوعات:

Response table for GRG. حسب Charles Sarala Rubi (21608723)

الموضوعات:

Effect of Reinforcement Percentage on GRG. حسب Charles Sarala Rubi (21608723)

الموضوعات:

Surface structure of fly ash particles. حسب Charles Sarala Rubi (21608723)

الموضوعات:

Elemental composition of Fly Ash. حسب Charles Sarala Rubi (21608723)

الموضوعات:

Composition of LM6 alloy. حسب Charles Sarala Rubi (21608723)

الموضوعات:

Image of the prepared sample (Pins and Disc). حسب Charles Sarala Rubi (21608723)

الموضوعات:

Micrograph of worn pin of LM6 alloy. حسب Charles Sarala Rubi (21608723)

الموضوعات:

Response graphs for GRG. حسب Charles Sarala Rubi (21608723)

الموضوعات:

Effect of B₄C& Fly ash on the hardness of AMCs. حسب Charles Sarala Rubi (21608723)

الموضوعات:

S1 File - حسب Luqiong Liu (11537092)

"…Compared with LPS treatment alone, BA significantly mitigated the reduction in the TEER, decreased FD-4 flux permeability, increased the mRNA expression of ZO-1 and Occludin, and normalized the distribution of ZO-1 and Occludin in Caco2 cells. …"

Experimental treatments and groups. حسب Luqiong Liu (11537092)

"…Compared with LPS treatment alone, BA significantly mitigated the reduction in the TEER, decreased FD-4 flux permeability, increased the mRNA expression of ZO-1 and Occludin, and normalized the distribution of ZO-1 and Occludin in Caco2 cells. …"

Primers for RT-qPCR. حسب Luqiong Liu (11537092)

"…Compared with LPS treatment alone, BA significantly mitigated the reduction in the TEER, decreased FD-4 flux permeability, increased the mRNA expression of ZO-1 and Occludin, and normalized the distribution of ZO-1 and Occludin in Caco2 cells. …"

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during letrozole treatment. حسب Kazuyoshi Ohkawa (836847)

الموضوعات:

Flowchart of patient selection in this study. حسب Kazuyoshi Ohkawa (836847)

الموضوعات:

Changes in the FIB-4 index in breast cancer patients with a FIB-4 index of ≥ 2.67 during letrozole and anastrozole treatment. حسب Kazuyoshi Ohkawa (836847)

الموضوعات:

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during anastrozole treatment. حسب Kazuyoshi Ohkawa (836847)

الموضوعات: